Evidence map›Paper›PMID 29554273›Full record

ArticleCarcinogenesis2018

The transformics assay: first steps for the development of an integrated approach to investigate the malignant cell transformation in vitro.

Maria Grazia Mascolo, Stefania Perdichizzi, Monica Vaccari, Francesca Rotondo, Cristina Zanzi, Sandro Grilli, Martin Paparella, Miriam N Jacobs, Annamaria Colacci

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Disease Animal Models for Cancer Research.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Maria Grazia MascoloCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Stefania PerdichizziCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Monica VaccariCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Francesca RotondoCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Cristina ZanziCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Sandro GrilliDepartment of Experimental, Diagnostic and Specialty Medicine, Section of Cancerology, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Martin PaparellaChemicals and Biocides, Environment Agency Austria, Vienna, Austria.
Miriam N JacobsDepartment of Toxicology, Centre for Radiation, Chemical and Environmental Hazards Public Health England, Chilton, Oxfordshire, UK.
Annamaria ColacciCenter for Environmental Toxicology, Agency for Prevention, Environment and Energy, Emilia-Romagna, Viale Filopanti, Bologna, Italy.
Agenzia Regionale Prevenzione e Ambiente della Regione Emilia-Romagna · ITEnvironment Agency Austria · ATPublic Health England · GBUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of alternative methods to animal testing is a priority in the context of regulatory toxicology. Carcinogenesis is a field where the demand for alternative methods is particularly high. The standard rodent carcinogenicity bioassay requires a large use of animals, high costs, prolonged duration and shows several limitations, which can affect the comprehension of the human relevance of animal carcinogenesis. The cell transformation assay (CTA) has long been debated as a possible in vitro test to study carcinogenesis. This assay provides an easily detectable endpoint of oncotransformation, which can be used to anchor the exposure to the acquisition of the malignant phenotype. However, the current protocols do not provide information on either molecular key events supporting the carcinogenesis process, nor the mechanism of action of the test chemicals. In order to improve the use of this assay in the integrated testing strategy for carcinogenesis, we developed the transformics method, which combines the CTA and transcriptomics, to highlight the molecular steps leading to in vitro malignant transformation. We studied 3-methylcholanthrene (3-MCA), a genotoxic chemical able to induce in vitro cell transformation, at both transforming and subtransforming concentrations in BALB/c 3T3 cells and evaluated the gene modulation at critical steps of the experimental protocol. The results gave evidence for the potential key role of the immune system and the possible involvement of the aryl hydrocarbon receptor (AhR) pathway as the initial steps of the in vitro transformation process induced by 3-MCA, suggesting that the initiating events are related to non-genotoxic mechanisms.

Indexed as

3T3 CellsAnimalsBiological AssayCarcinogenesisCarcinogenicity TestsCarcinogensCell Transformation, NeoplasticMethylcholanthreneMiceMice, Inbred BALB CReceptors, Aryl HydrocarbonCarcinogensMethylcholanthreneReceptors, Aryl Hydrocarbon

Identifiers

PMID29554273
PMCPMC6031005
OpenAlexW2790092679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.